Annual CFI
$139.56 M
-$226.27 M-61.85%
31 December 2023
Summary:
Nektar Therapeutics annual cash flow from investing activities is currently $139.56 million, with the most recent change of -$226.27 million (-61.85%) on 31 December 2023. During the last 3 years, it has fallen by -$356.65 million (-71.87%). NKTR annual CFI is now -71.87% below its all-time high of $496.21 million, reached on 31 December 2020.NKTR Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$46.12 M
+$29.13 M+171.56%
30 September 2024
Summary:
Nektar Therapeutics quarterly cash flow from investing activities is currently $46.12 million, with the most recent change of +$29.13 million (+171.56%) on 30 September 2024. Over the past year, it has dropped by -$10.30 million (-18.25%). NKTR quarterly CFI is now -76.68% below its all-time high of $197.77 million, reached on 31 March 2020.NKTR Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$99.74 M
-$10.30 M-9.36%
30 September 2024
Summary:
Nektar Therapeutics TTM cash flow from investing activities is currently $99.74 million, with the most recent change of -$10.30 million (-9.36%) on 30 September 2024. Over the past year, it has dropped by -$62.46 million (-38.51%). NKTR TTM CFI is now -81.82% below its all-time high of $548.54 million, reached on 30 June 2020.NKTR TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NKTR Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -61.9% | -18.3% | -38.5% |
| 3 y3 years | -71.9% | +5656.1% | -43.1% |
| 5 y5 years | +110.1% | -20.8% | -37.3% |
NKTR Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -71.9% | at low | -64.6% | +5656.1% | -77.6% | at low |
| 5 y | 5 years | -71.9% | +110.1% | -76.7% | +5656.1% | -81.8% | at low |
| alltime | all time | -71.9% | +110.1% | -76.7% | +105.2% | -81.8% | +106.9% |
Nektar Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $46.12 M(+171.6%) | $99.74 M(-9.4%) |
| June 2024 | - | $16.98 M(-11.8%) | $110.03 M(-6.9%) |
| Mar 2024 | - | $19.26 M(+10.8%) | $118.22 M(-15.3%) |
| Dec 2023 | $139.56 M(-61.9%) | $17.38 M(-69.2%) | $139.56 M(-14.0%) |
| Sept 2023 | - | $56.41 M(+124.1%) | $162.19 M(-25.3%) |
| June 2023 | - | $25.17 M(-38.0%) | $217.18 M(-21.4%) |
| Mar 2023 | - | $40.60 M(+1.5%) | $276.15 M(-24.5%) |
| Dec 2022 | $365.83 M(+80.4%) | $40.01 M(-64.1%) | $365.83 M(-18.0%) |
| Sept 2022 | - | $111.39 M(+32.4%) | $446.02 M(+33.6%) |
| June 2022 | - | $84.15 M(-35.4%) | $333.79 M(+3.5%) |
| Mar 2022 | - | $130.28 M(+8.4%) | $322.60 M(+59.1%) |
| Dec 2021 | $202.78 M(-59.1%) | $120.20 M(<-9900.0%) | $202.78 M(+15.7%) |
| Sept 2021 | - | -$830.00 K(-101.1%) | $175.32 M(-22.0%) |
| June 2021 | - | $72.95 M(+597.6%) | $224.82 M(-27.2%) |
| Mar 2021 | - | $10.46 M(-88.7%) | $308.90 M(-37.7%) |
| Dec 2020 | $496.21 M(+139.8%) | $92.74 M(+90.6%) | $496.21 M(-7.9%) |
| Sept 2020 | - | $48.67 M(-69.0%) | $538.95 M(-1.7%) |
| June 2020 | - | $157.04 M(-20.6%) | $548.54 M(+31.6%) |
| Mar 2020 | - | $197.77 M(+46.0%) | $416.79 M(+101.5%) |
| Dec 2019 | $206.89 M(-115.0%) | $135.48 M(+132.6%) | $206.89 M(+30.2%) |
| Sept 2019 | - | $58.25 M(+130.3%) | $158.94 M(-130.5%) |
| June 2019 | - | $25.29 M(-308.4%) | -$520.58 M(-63.9%) |
| Mar 2019 | - | -$12.14 M(-113.9%) | -$1.44 B(+4.4%) |
| Dec 2018 | -$1.38 B(+4689.9%) | $87.54 M(-114.1%) | -$1.38 B(-4.5%) |
| Sept 2018 | - | -$621.27 M(-30.5%) | -$1.44 B(+59.8%) |
| June 2018 | - | -$894.41 M(-1955.2%) | -$903.92 M(-2883.8%) |
| Mar 2018 | - | $48.21 M(+109.8%) | $32.47 M(-212.7%) |
| Dec 2017 | -$28.81 M(-65.0%) | $22.98 M(-128.5%) | -$28.81 M(-85.1%) |
| Sept 2017 | - | -$80.69 M(-292.2%) | -$193.89 M(+128.6%) |
| June 2017 | - | $41.97 M(-421.1%) | -$84.82 M(-35.6%) |
| Mar 2017 | - | -$13.07 M(-90.8%) | -$131.72 M(+59.8%) |
| Dec 2016 | -$82.40 M(+474.8%) | -$142.10 M(-600.7%) | -$82.40 M(-257.0%) |
| Sept 2016 | - | $28.38 M(-676.5%) | $52.50 M(+76.0%) |
| June 2016 | - | -$4.92 M(-113.6%) | $29.82 M(-195.4%) |
| Mar 2016 | - | $36.25 M(-603.1%) | -$31.25 M(+118.0%) |
| Dec 2015 | -$14.34 M(-61.8%) | -$7.21 M(-226.3%) | -$14.34 M(-55.1%) |
| Sept 2015 | - | $5.71 M(-108.6%) | -$31.94 M(-1375.5%) |
| June 2015 | - | -$65.99 M(-224.1%) | $2.50 M(-96.6%) |
| Mar 2015 | - | $53.16 M(-314.3%) | $73.80 M(-296.4%) |
| Dec 2014 | -$37.57 M(-175.3%) | -$24.81 M(-161.8%) | -$37.57 M(-60.4%) |
| Sept 2014 | - | $40.15 M(+657.2%) | -$94.91 M(+1.7%) |
| June 2014 | - | $5.30 M(-109.1%) | -$93.28 M(+79.4%) |
| Mar 2014 | - | -$58.21 M(-29.1%) | -$51.99 M(-204.2%) |
| Dec 2013 | $49.91 M(-55.8%) | -$82.15 M(-296.6%) | $49.91 M(-74.3%) |
| Sept 2013 | - | $41.78 M(-10.3%) | $194.29 M(+32.1%) |
| June 2013 | - | $46.60 M(+6.7%) | $147.12 M(+35.9%) |
| Mar 2013 | - | $43.69 M(-29.8%) | $108.28 M(-4.2%) |
| Dec 2012 | $113.02 M(-201.0%) | $62.23 M(-1254.3%) | $113.02 M(+73.4%) |
| Sept 2012 | - | -$5.39 M(-169.5%) | $65.19 M(-47.1%) |
| June 2012 | - | $7.76 M(-84.0%) | $123.32 M(-10.9%) |
| Mar 2012 | - | $48.42 M(+236.3%) | $138.36 M(-223.6%) |
| Dec 2011 | -$111.95 M(-769.8%) | $14.40 M(-72.7%) | -$111.95 M(-22.0%) |
| Sept 2011 | - | $52.73 M(+131.3%) | -$143.52 M(-22.3%) |
| June 2011 | - | $22.80 M(-111.3%) | -$184.75 M(-0.8%) |
| Mar 2011 | - | -$201.88 M(+1076.3%) | -$186.19 M(-1214.1%) |
| Dec 2010 | $16.71 M(-111.2%) | -$17.16 M(-249.3%) | $16.71 M(-120.9%) |
| Sept 2010 | - | $11.49 M(-46.2%) | -$80.03 M(-49.3%) |
| June 2010 | - | $21.36 M(+1992.2%) | -$157.77 M(+0.3%) |
| Mar 2010 | - | $1.02 M(-100.9%) | -$157.30 M(+5.5%) |
| Dec 2009 | -$149.03 M | -$113.90 M(+71.9%) | -$149.03 M(-210.2%) |
| Sept 2009 | - | -$66.25 M(-403.5%) | $135.30 M(-46.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | $21.83 M(+135.0%) | $252.88 M(-2.2%) |
| Mar 2009 | - | $9.29 M(-94.5%) | $258.56 M(-5.9%) |
| Dec 2008 | $274.65 M(-941.1%) | $170.43 M(+232.0%) | $274.65 M(-928.6%) |
| Sept 2008 | - | $51.33 M(+86.6%) | -$33.15 M(-30.7%) |
| June 2008 | - | $27.51 M(+8.4%) | -$47.85 M(-46.8%) |
| Mar 2008 | - | $25.39 M(-118.5%) | -$90.00 M(+175.6%) |
| Dec 2007 | -$32.66 M(-72.1%) | -$137.37 M(-475.1%) | -$32.66 M(-210.0%) |
| Sept 2007 | - | $36.62 M(-350.1%) | $29.70 M(-856.9%) |
| June 2007 | - | -$14.64 M(-117.7%) | -$3.92 M(-94.2%) |
| Mar 2007 | - | $82.73 M(-210.3%) | -$68.17 M(-41.7%) |
| Dec 2006 | -$116.88 M(-460.7%) | -$75.01 M(-2599.6%) | -$116.88 M(-4.0%) |
| Sept 2006 | - | $3.00 M(-103.8%) | -$121.71 M(+47.1%) |
| June 2006 | - | -$78.89 M(-331.9%) | -$82.75 M(-313.5%) |
| Mar 2006 | - | $34.02 M(-142.6%) | $38.75 M(+19.6%) |
| Dec 2005 | $32.40 M(-136.4%) | -$79.84 M(-290.3%) | $32.40 M(-81.1%) |
| Sept 2005 | - | $41.96 M(-1.5%) | $171.05 M(+11.4%) |
| June 2005 | - | $42.61 M(+54.0%) | $153.60 M(+85.4%) |
| Mar 2005 | - | $27.67 M(-52.9%) | $82.84 M(-193.2%) |
| Dec 2004 | -$88.91 M(-2283.4%) | $58.81 M(+140.0%) | -$88.91 M(-30.8%) |
| Sept 2004 | - | $24.50 M(-187.1%) | -$128.40 M(-37.0%) |
| June 2004 | - | -$28.14 M(-80.5%) | -$203.78 M(+22.3%) |
| Mar 2004 | - | -$144.08 M(-846.0%) | -$166.60 M(-4191.4%) |
| Dec 2003 | $4.07 M(-89.9%) | $19.31 M(-138.0%) | $4.07 M(-138.6%) |
| Sept 2003 | - | -$50.88 M(-662.7%) | -$10.56 M(-112.8%) |
| June 2003 | - | $9.04 M(-66.0%) | $82.17 M(+20.9%) |
| Mar 2003 | - | $26.59 M(+467.9%) | $67.94 M(+68.5%) |
| Dec 2002 | $40.32 M(-152.3%) | $4.68 M(-88.8%) | $40.32 M(-2.2%) |
| Sept 2002 | - | $41.86 M(-906.2%) | $41.21 M(-124.7%) |
| June 2002 | - | -$5.19 M(+403.6%) | -$166.77 M(+483.6%) |
| Mar 2002 | - | -$1.03 M(-118.5%) | -$28.58 M(-62.9%) |
| Dec 2001 | -$77.04 M(-74.3%) | $5.58 M(-103.4%) | -$77.04 M(-69.9%) |
| Sept 2001 | - | -$166.13 M(-224.9%) | -$256.10 M(+269.8%) |
| June 2001 | - | $133.00 M(-368.7%) | -$69.25 M(-70.4%) |
| Mar 2001 | - | -$49.49 M(-71.5%) | -$234.24 M(-21.9%) |
| Dec 2000 | -$299.75 M(+263.6%) | -$173.49 M(-937.1%) | -$299.75 M(+38.1%) |
| Sept 2000 | - | $20.72 M(-164.8%) | -$217.10 M(-7.1%) |
| June 2000 | - | -$31.99 M(-72.2%) | -$233.72 M(+20.4%) |
| Mar 2000 | - | -$115.00 M(+26.6%) | -$194.07 M(+135.4%) |
| Dec 1999 | -$82.44 M(+1168.3%) | -$90.84 M(-2315.6%) | -$82.44 M(+379.3%) |
| Sept 1999 | - | $4.10 M(-46.5%) | -$17.20 M(-32.3%) |
| June 1999 | - | $7.66 M(-327.9%) | -$25.39 M(+83.4%) |
| Mar 1999 | - | -$3.36 M(-86.9%) | -$13.84 M(+113.0%) |
| Dec 1998 | -$6.50 M(-92.3%) | -$25.60 M(+525.3%) | -$6.50 M(-76.0%) |
| Sept 1998 | - | -$4.09 M(-121.3%) | -$27.13 M(-42.7%) |
| June 1998 | - | $19.21 M(+382.5%) | -$47.33 M(-28.8%) |
| Mar 1998 | - | $3.98 M(-108.6%) | -$66.44 M(-21.6%) |
| Dec 1997 | -$84.71 M(+2129.3%) | -$46.23 M(+90.2%) | -$84.71 M(+146.4%) |
| Sept 1997 | - | -$24.30 M(<-9900.0%) | -$34.39 M(+406.8%) |
| June 1997 | - | $101.00 K(-100.7%) | -$6.79 M(-64.6%) |
| Mar 1997 | - | -$14.29 M(-448.4%) | -$19.19 M(+404.9%) |
| Dec 1996 | -$3.80 M(-71.9%) | $4.10 M(+24.2%) | -$3.80 M(-33.3%) |
| Sept 1996 | - | $3.30 M(-126.8%) | -$5.70 M(-50.0%) |
| June 1996 | - | -$12.30 M(-1218.2%) | -$11.40 M(+7.5%) |
| Mar 1996 | - | $1.10 M(-50.0%) | -$10.60 M(-21.5%) |
| Dec 1995 | -$13.50 M(+800.0%) | $2.20 M(-191.7%) | -$13.50 M(+32.4%) |
| Sept 1995 | - | -$2.40 M(-79.1%) | -$10.20 M(-11.3%) |
| June 1995 | - | -$11.50 M(+538.9%) | -$11.50 M(+210.8%) |
| Mar 1995 | - | -$1.80 M(-132.7%) | -$3.70 M(+146.7%) |
| Dec 1994 | -$1.50 M | $5.50 M(-248.6%) | -$1.50 M(-78.6%) |
| Sept 1994 | - | -$3.70 M(0.0%) | -$7.00 M(+112.1%) |
| June 1994 | - | -$3.70 M(-1025.0%) | -$3.30 M(-925.0%) |
| Mar 1994 | - | $400.00 K | $400.00 K |
FAQ
- What is Nektar Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Nektar Therapeutics?
- What is Nektar Therapeutics annual CFI year-on-year change?
- What is Nektar Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Nektar Therapeutics?
- What is Nektar Therapeutics quarterly CFI year-on-year change?
- What is Nektar Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Nektar Therapeutics?
- What is Nektar Therapeutics TTM CFI year-on-year change?
What is Nektar Therapeutics annual cash flow from investing activities?
The current annual CFI of NKTR is $139.56 M
What is the all time high annual CFI for Nektar Therapeutics?
Nektar Therapeutics all-time high annual cash flow from investing activities is $496.21 M
What is Nektar Therapeutics annual CFI year-on-year change?
Over the past year, NKTR annual cash flow from investing activities has changed by -$226.27 M (-61.85%)
What is Nektar Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of NKTR is $46.12 M
What is the all time high quarterly CFI for Nektar Therapeutics?
Nektar Therapeutics all-time high quarterly cash flow from investing activities is $197.77 M
What is Nektar Therapeutics quarterly CFI year-on-year change?
Over the past year, NKTR quarterly cash flow from investing activities has changed by -$10.30 M (-18.25%)
What is Nektar Therapeutics TTM cash flow from investing activities?
The current TTM CFI of NKTR is $99.74 M
What is the all time high TTM CFI for Nektar Therapeutics?
Nektar Therapeutics all-time high TTM cash flow from investing activities is $548.54 M
What is Nektar Therapeutics TTM CFI year-on-year change?
Over the past year, NKTR TTM cash flow from investing activities has changed by -$62.46 M (-38.51%)